SETH LERNER to Chemotherapy, Adjuvant
This is a "connection" page, showing publications SETH LERNER has written about Chemotherapy, Adjuvant.
Connection Strength
1.156
-
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer. N Engl J Med. 2024 Oct 03; 391(13):1206-1216.
Score: 0.217
-
Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int. 2015 Jul; 116(1):44-9.
Score: 0.112
-
Neoadjuvant chemotherapy preceding cystectomy for bladder cancer. Expert Opin Pharmacother. 2008 Aug; 9(11):1885-93.
Score: 0.071
-
Neoadjuvant chemotherapy for bladder cancer. Oncology (Williston Park). 2007 Dec; 21(14):1673-81; discussion 1686-8, 1691, 1694.
Score: 0.067
-
Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422.
Score: 0.063
-
Bladder cancer clinical trials. Urol Oncol. 2005 Jul-Aug; 23(4):275-9.
Score: 0.057
-
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 08 01; 7(8):e2425288.
Score: 0.054
-
Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. Eur Urol. 2024 Oct; 86(4):297-300.
Score: 0.053
-
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial. Eur Urol. 2024 Sep; 86(3):258-264.
Score: 0.053
-
Perioperative chemotherapy in locally advanced bladder cancer. Lancet. 2003 Jun 07; 361(9373):1922-3.
Score: 0.049
-
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314. Eur Urol Oncol. 2023 10; 6(5):516-524.
Score: 0.049
-
Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncol. 2022 Jul; 18(21):2599-2614.
Score: 0.046
-
Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. Urol Oncol. 2019 07; 37(7):430-436.
Score: 0.037
-
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Eur Urol. 2017 10; 72(4):544-554.
Score: 0.032
-
Prognostic Significance of Neutrophilic Infiltration in Benign Lymph Nodes in Patients with Muscle-invasive Bladder Cancer. Eur Urol Focus. 2017 02; 3(1):130-135.
Score: 0.030
-
Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. Eur Urol. 2015 Aug; 68(2):238-53.
Score: 0.028
-
Radical cystectomy in regionally advanced bladder cancer. Urol Clin North Am. 1992 Nov; 19(4):713-23.
Score: 0.024
-
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2012 Sep; 62(3):523-33.
Score: 0.023
-
Perioperative chemotherapy for upper tract urothelial cancer. Nat Rev Urol. 2012 Apr 10; 9(5):266-73.
Score: 0.023
-
The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res. 2010 Sep 01; 16(17):4461-7.
Score: 0.020
-
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009 Sep 15; 115(18):4104-9.
Score: 0.019
-
Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. BJU Int. 2008 Jun; 101(11):1356-61.
Score: 0.017
-
Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. Urology. 2003 Feb; 61(2):359-64.
Score: 0.012